# Debate Matchup Judgment Report

**Claude Opus 4.8 (high)** vs **Claude Sonnet 5 (high)**

- Paired result: **Tie**
- Mean entertainment: `8.17 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Widespread adoption of continuous glucose monitors by non-diabetic people will improve public health more than it will fuel anxiety and over-medicalization.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__s0__tpl_placement_active_20260320f.md): PRO = **Claude Opus 4.8 (high)**, CON = **Claude Sonnet 5 (high)**
- [Debate B transcript](../../../transcripts/prop_0650__claude-sonnet-5-high__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f.md): PRO = **Claude Sonnet 5 (high)**, CON = **Claude Opus 4.8 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_20260814a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Opus 4.8 (high)**, CON = **Claude Sonnet 5 (high)**
- Judged result: Split `2-1` for **Claude Sonnet 5 (high)**.
- Entertainment scores: `8`, `8`, `8`
- Mean signed raw margin (PRO+): `-0.60`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = Claude Opus 4.8 (high) (PRO); B = Claude Sonnet 5 (high) (CON) | Claude Sonnet 5 (high) | -1.8 | -1.53 | 8.0 |
| Kimi K2.6 | A = Claude Sonnet 5 (high) (CON); B = Claude Opus 4.8 (high) (PRO) | Claude Opus 4.8 (high) | +1.5 | +1.70 | 8.0 |
| Qwen 3.7 Max | A = Claude Sonnet 5 (high) (CON); B = Claude Opus 4.8 (high) (PRO) | Claude Sonnet 5 (high) | -1.5 | -1.27 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = Claude Opus 4.8 (high) (PRO); B = Claude Sonnet 5 (high) (CON)): Side B won by successfully distinguishing the value of clinical data from the dangers of mass unsupervised data. B's use of the whole-body MRI analogy perfectly illustrated the "denominator" problem in mass screening, neutralizing A's strongest claim about catching silent prediabetes. B also effectively rebutted A's behavioral loop argument by noting that flattening a normal spike is exactly the over-medicalization the motion warns against.
  Most decisive rebuttal noted: Side B's Rebuttal 2 was decisive, specifically the answer to A's pressure question about targeted screening. B explained that imperfect data becomes dangerous when stripped of a doctor's clinical context, cleanly separating B's support for targeted screening from A's defense of mass consumer adoption.
- **Kimi K2.6** (A = Claude Sonnet 5 (high) (CON); B = Claude Opus 4.8 (high) (PRO)): PRO successfully established that the baseline population is not clearly "healthy," undermining CON's worry-well framing by showing silent prediabetes evades risk-factor screening and widespread adoption is the only net that catches those hidden cases. CON landed strong blows on ambiguous thresholds and clinical context, but never fully resolved the catch-22 that targeted screening relies on the same uncertain data. PRO's reversible-versus-irreversible weighing crystallized the asymmetry: transient anxiety and clumsy apps self-correct, while undetected metabolic decline hardens into permanent organ damage. That framing, sustained across rebuttals and closing, gave PRO the cleaner route to victory.
  Most decisive rebuttal noted: PRO's second rebuttal pressuring the symmetry in CON's position: CON cannot endorse targeted glucose screening while claiming the same glucose data is unusable noise for consumers, since the line between "healthy" and "at-risk" is exactly what is unknown without monitoring.
- **Qwen 3.7 Max** (A = Claude Sonnet 5 (high) (CON); B = Claude Opus 4.8 (high) (PRO)): CON wins by successfully applying core public health screening principles to the motion. The "needle-in-a-haystack" and whole-body MRI analogies effectively neutralized PRO's "cast a wide net" argument by highlighting the denominator problem: the costs of anxiety and over-medicalization apply to the millions of healthy adopters, while the benefits apply only to the rare undetected cases. CON's insistence on the necessity of clinical interpreters and established thresholds further solidified the over-medicalization harm, leaving PRO's "reversible vs. irreversible" closing framework undermined by the sheer scale of the healthy majority.
  Most decisive rebuttal noted: CON's Rebuttal 2, specifically the A1 response using the whole-body MRI analogy to explain why mass deployment is the wrong instrument for a silent but low-prevalence hidden condition, effectively dismantling PRO's "wide net" justification.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0650__claude-sonnet-5-high__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Sonnet 5 (high)**, CON = **Claude Opus 4.8 (high)**
- Judged result: Split `2-1` for **Claude Opus 4.8 (high)**.
- Entertainment scores: `9`, `8`, `8`
- Mean signed raw margin (PRO+): `-0.57`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Gemini 3.1 Pro Preview | A = Claude Sonnet 5 (high) (PRO); B = Claude Opus 4.8 (high) (CON) | Claude Sonnet 5 (high) | +1.2 | +1.02 | 9.0 |
| Kimi K2.6 | A = Claude Opus 4.8 (high) (CON); B = Claude Sonnet 5 (high) (PRO) | Claude Opus 4.8 (high) | -0.9 | -1.02 | 8.0 |
| Qwen 3.7 Max | A = Claude Opus 4.8 (high) (CON); B = Claude Sonnet 5 (high) (PRO) | Claude Opus 4.8 (high) | -2.0 | -1.70 | 8.0 |

### Judge Notes

- **Gemini 3.1 Pro Preview** (A = Claude Sonnet 5 (high) (PRO); B = Claude Opus 4.8 (high) (CON)): Side A wins by establishing a highly durable asymmetry between the 'soft, correctable' harms of anxiety and the 'hard, compounding' harms of metabolic decline. Side B attempts to sever Side A's solvency by arguing the device doesn't officially diagnose or refer to care, but Side A successfully uses the analogy of blood pressure cuffs and step counters to show how personalized data drives behavior and care-seeking regardless of built-in clinical referrals.
  Most decisive rebuttal noted: Side A's second rebuttal exposing the contradiction in Side B's case: a device cannot simultaneously be completely useless because it merely 're-teaches free advice' and powerfully dangerous as an 'engine of an orthorexia epidemic.'
- **Kimi K2.6** (A = Claude Opus 4.8 (high) (CON); B = Claude Sonnet 5 (high) (PRO)): CON successfully identified and exploited the load-bearing weakness in PRO's case: the missing link between CGM data and actual clinical outcomes. While PRO established an undisputed epidemiological problem (widespread undiagnosed prediabetes), CON persuasively argued that the device constitutes "surveillance without a safety net"—generating numbers without validated non-diabetic targets, reliable referral pathways, or proof that awareness converts into prevented harms. CON's rebuttal dismantled PRO's blood-pressure analogy by distinguishing validated clinical targets from misapplied lab thresholds, and CON's "certain cost versus speculative benefit" framing survived PRO's attempts to reverse it. PRO's soft-cost/hard-cost asymmetry was rhetorically powerful but analytically undermined by CON's insistence that prevalence alone does not equal prevented morbidity without a proven per-person effect. The debate was competitive on both sides, but CON left the more durable route to victory intact after the full exchange.
  Most decisive rebuttal noted: CON's Rebuttal 2 answer that "behavior change is not the same as health improvement," distinguishing home blood pressure cuffs (validated target, proven outcome) from CGMs for non-diabetics (behavior toward "flatness" with no established benefit), which neutralized PRO's central analogy and left PRO's mechanism speculative.
- **Qwen 3.7 Max** (A = Claude Opus 4.8 (high) (CON); B = Claude Sonnet 5 (high) (PRO)): Side A won by decisively breaking Side B's causal link between consumer CGM adoption and public health improvement. Side A effectively argued that without a validated clinical target for non-diabetics, the device promotes arbitrary "flatness" chasing (risking orthorexia) rather than meaningful health improvement. Side A also successfully contrasted the certain, immediate costs of the device with the speculative nature of its benefits, dismantling Side B's reliance on the sheer prevalence of undiagnosed prediabetes by showing the device lacks a proven clinical conversion mechanism for those users.
  Most decisive rebuttal noted: Side A's dismantling of Side B's 140 mg/dL threshold, exposing it as a supervised lab diagnostic protocol misapplied to everyday snacking, which perfectly crystallized Side A's core argument that the device generates "noise dressed up as insight" rather than actionable clinical data.

## Technical metadata

- Evaluation scope: `judge_judge_blend_20260814a__debate_all_templates`
- Topic ID: `prop_0650`
- Side-swap group ID: `prop_0650__claude-opus-4-8-adaptive__claude-sonnet-5-high__tpl_placement_active_20260320f`
- Raw paired winner: **Tie**
- Mean normalized margin for Claude Opus 4.8 (high): `+0.10`
- Complete side swap: `yes`
- Included in ratings: `yes`
